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soy-Based therapeutic Baby 
Formulas: testable Hypotheses 
regarding the pros and Cons
Cara J. Westmark*
Department of Neurology, University of Wisconsin, Madison, WI, USA
Soy-based infant formulas have been consumed in the United States since 1909, and 
currently constitute a significant portion of the infant formula market. There are efforts 
underway to generate genetically modified soybeans that produce therapeutic agents 
of interest with the intent to deliver those agents in a soy-based infant formula platform. 
The threefold purpose of this review article is to first discuss the pros and cons of soy-
based infant formulas, then present testable hypotheses to discern the suitability of a soy 
platform for drug delivery in babies, and finally start a discussion to inform public policy 
on this important area of infant nutrition.
Keywords: soy-based infant formula, phytoestrogens, glyphosate, genetically modified, seizures, necrotizing 
enterocolitis
introdUCtion
Soy-based infant formulas (SIFs) have been in use in the United States for over a century. 
Proponents of SIF argue that the long time and widespread use of SIF in the general popula-
tion without documented adverse health effects proves they are a safe, healthy, and economical 
alternative for babies with cow milk allergies, lactose intolerance, galactosemia, gastrointestinal 
issues, or vegetarian preference. Opponents of SIF counter that the safety of SIF has not been 
rigorously tested, particularly health effects associated with the phytoestrogens and agrochemicals 
in soy products. Recently, an article entitled, “Transgenic Soybean Production of Bioactive Human 
Epidermal Growth Factor (EGF),” was published in PLoS One by the Herman Laboratory at the 
University of Arizona. The authors conclude that soybean seeds can be employed as biofactories for 
the production of therapeutic agents such as EGF with delivery in a soymilk platform. Our goals 
in this article are to review the available evidence regarding the safety and efficacy of SIF, present 
testable hypothesis that address the adverse arguments, and thus provide a framework for a public 
policy debate regarding the feasibility and bioethics of developing therapeutic SIF.
tHe eVidenCe sUpportinG soy-Based 
tHerapeUtiC inFant ForMULas
Three main arguments in support of developing therapeutic SIF are as follows: (1) SIFs have been 
safely used for over a century with minimal documented adverse health effects, (2) soy protein is 
associated with many health benefits in adults, and (3) soybeans are an economical means to generate 
and deliver therapeutics. First, we will review the literature in regard to randomized controlled trials 
(RCT) with SIF, then we will discuss soy-associated health benefits, and finally, we will consider the 
biological and economic advantages of utilizing SIF as a drug delivery platform.
taBLe 1 | pubMed literature search with keywords “soy” and “infant” and “Formula” and the Filters “From 2005/01/01 to 2016/07/19” and “Clinical trial.”
1. Soy protein-based infant formulas with supplemental fructooligosaccharides: gastrointestinal tolerance and hydration status in 
newborn infants
Lasekan et al. (1)
2. Compared with feeding infants breast milk or cow milk formula, soy formula feeding does not affect subsequent reproductive organ 
size at 5 years of age
Andres et al. (2)
3. Lactose-free milk or soy-based formulas do not improve caregivers’ distress or perceptions of difficult infant behavior Sherman et al. (3)
4. The use of linear programing to determine whether a formulated complementary food product can ensure adequate nutrients for 
6- to 11-month-old Cambodian infants
Skau et al. (4)
5. Formula selection for management of children with cow’s milk allergy (CMA) influences the rate of acquisition of tolerance: a 
prospective multicenter study
Berni Canani et al. (5)
6. Body fat and bone mineral content of infants fed breast milk, cow’s milk formula, or soy formula during the first year of life Andres et al. (6)
7. Developmental status of 1-year-old infants fed breast milk, cow’s milk formula, or soy formula Andres et al. (7)
8. Evaluation of therapeutic effects of three hypoallergenic formula in infants with cow’s milk protein allergy Yan et al. (8) (in Chinese)
9. Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk Setchell et al. (9)
10. Effect of a partially hydrolyzed whey infant formula at weaning on risk of allergic disease in high-risk children: a randomized 
controlled trial
Lowe et al. (10)
11. Effect of feeding a formula supplemented with long-chain polyunsaturated fatty acids at 14 weeks improves the ex vivo response to 
a mitogen and reduces the response to soy protein in infants at low risk for allergy
Field et al. (11)
12. The effect of partially hyrdrolysed formula based on rice protein in the treatment of infants with cow’s milk protein allergy Reche et al. (12)
13. Effect of milk-based infant formula and soy-based infant formula (SIF) on in situ demineralization of human primary enamel de Mazer Papa et al. (13)
14. Impact of dietary regimen on the duration of CMA: a random allocation study Terracciano et al. (14)
15. Infant formula promotes bone growth in neonatal piglets by enhancing osteoblastogenesis through bone morphogenic protein 
signaling
Chen et al. (15)
16. Comparison of yogurt, soybean, casein, and amino-acid-based diets in children with persistent diarrhea de Mattos et al. (16)
17. Early infant diet and the omega-3 fatty acid docosahexanenoic acid (DHA): effects on resting cardiovascular activity and behavioral 
development during the first half-year of life
Pivik et al. (17)
18. Clinical response to two commonly used switch formulas occurs within 1 day Berseth et al. (18)
19. Comparisons of a chicken-based formula with soy-based formula in infants with CMA Jirapinyo et al. (19)
20. SIF supplemented with DHA and ARA supports growth and increases circulating levels of these fatty acids in infants Hoffman et al. (20)
21. The effect of early nutritional supplementation with a mixture of probiotic, prebiotic, fiber, and micronutrients in infants with acute 
diarrhea in Indonesia
Agustina et al. (21)
22. Growth of infants with immunoglobulin E (IgE)-mediated CMA fed different formulas in the complementary feeding period Agostoni et al. (22)
23. Palatability of hydrolyzates and other substitution formulas for CMA children: a comparative study of taste, smell, and texture 
evaluated by healthy volunteers
Pedrosa et al. (23)
24. A hydrolyzed rice-based formula is tolerated by children with CMA: a multicenter study Fiocchi et al. (24)
25. Decreased regurgitation with a soy formula containing added soy fiber Ostrom et al. (25)
26. Feeding a soy formula to children with CMA: the development of IgE-mediated allergy to soy and peanuts Klemola et al. (26)
27. The almond milk: a new approach to the management of CMA/intolerance in infants Salpietro et al. (27)
28. A follow-up study of nutrient intake, nutritional status, and growth in infants with CMA fed either soy formula or an extensively 
hydrolyzed whey formula
Seppo et al. (28)
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In terms of documented health effects, RCT are the gold stand-
ard in testing the safety and efficacy of medical interventions. 
RCT are carefully planned clinical studies testing a treatment or 
exposure in patients. The methodologies are designed to reduce 
bias and systematic errors and provide sound evidence of cause 
and effect. Thus, we reviewed the literature in regard to RCT 
with SIF. First, we searched PubMed with the keywords “Soy” 
AND “Infant” AND “Formula” and the filters “From 2005/01/01 
to 2016/07/19” AND “Clinical Trial.” Twenty-eight articles were 
returned (Table 1), of which 27 were available in English. Eleven 
of these articles regarded a side-by-side comparison of the effects 
of SIF with breast milk and/or cow milk-based formula on infant 
health (reviewed below). The remaining 16 SIF RCT are reviewed 
in the Data Sheet S1 in Supplementary Material.
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siF rCt Literature review 2005–2016
The Andres study (2) was a prospective, longitudinal study in 
children from the Beginnings Study who were recruited from 
the Central Arkansas region between ages 1 and 2 months of age 
and were tested at 5 years of age for reproductive organ volume 
and structural characteristics in response to infant diet. The 
population included 101 children (50 boys and 51 girls) aged 
5 years who were breast-fed (n = 35) or fed cow milk formula 
(n =  32) or SIF (n =  34) as infants. The independent variable 
was infant diet, and the dependent variables were breast bud, 
uterus, ovaries, prostate, and testes volumes and characteristics 
as assessed by ultrasonography. The outcome in both genders 
was no significant difference in reproductive organ volume or 
structural characteristics.
The Sherman study (3) was a double-blind, multicenter, 
 parallel-group, randomized study in infants to assess formula 
change on fussiness and caregiver distress. The study popula-
tion included dyads of infants (2–12  weeks of age; mean age 
4.97  weeks) and female caregivers. The infants had been fed a 
milk-based formula containing lactose for at least 5  days as 
the sole diet at the time of enrollment and were experiencing 
common feeding problems (i.e., fussiness/crying/cramping, 
gas, or diarrhea). Infants were randomized to receive lactose-
free milk-based formula (n = 96), lactose-free SIF (n = 97), or 
milk-based, lactose-containing formula (n =  103) as the sole 
diet for 14 days. The independent variable was formula and the 
dependent variables were answers to the Infant Characteristics 
Questionnaire and measures of caregiver distress. The outcome 
was no significant benefit in reducing infant and maternal distress 
in response to milk-based or SIF lactose-free formulas compared 
with a lactose-containing milk-based formula.
The Berni Canani study (5) was a prospective, open, 
non-randomized evaluation over a 12-month period of the 
effect of different dietary management strategies on the rate 
of acquisition of tolerance in otherwise healthy children with 
CMA. The population included 260 male and female children 
aged 1–12  months. The study population was divided into 
five formula groups: (1) extensively hydrolyzed casein for-
mula (EHCF), (2) EHCF +  Lactobacillus rhamnosus GG, (3) 
hydrolyzed rice formula, (4) SIF, and (5) amino acid-based 
formula. The independent variable was formula choice and the 
dependent variable was tolerance to cow’s milk. The outcome 
was the rate of children acquiring oral tolerance after 12 months 
was significantly higher in groups receiving EHCF or EHCF + 
L.  rhamnosus GG.
The Andres study (6) was a 12-month longitudinal study to 
characterize growth, fat mass, free fat mass, and bone mineral 
content (BMC) in healthy infants fed breast milk versus cow’s 
milk formula or SIF during the first year of life. The population 
included 344 infants aged 3, 6, 9, and 12  months, both male 
and female (the Beginnings Study). The ethnicity was 9.7% 
African-American, 84.5% Caucasian, and 5.8% unknown. 
Socioeconomic status (SES) was 46.8 ±  11.6 on Hollingshead 
Four-Factor Index. Growth was evaluated using standard 
anthropometric techniques and body composition was assessed 
using dual-energy X-ray absorption. Mixed-effects models with 
repeated measures were used to adjust for race, SES, gestational 
age, birth weight, birth length, sex, age, and diet history. The 
independent variable was formula choice, and the dependent 
variables were body composition and BMC. The outcome was 
that infants fed breast milk had higher fat mass at 3 months and 
lower free fat mass at 6–12 months. Infants fed SIF had greater 
free fat mass at age 6 and 9  months compared to cow milk 
formula. BMC was higher in infants fed breast milk and lower 
in infants fed SIF at 3 months. BMC was higher in infants fed 
SIF at 12 months. Body composition data showed that soy-fed 
infants were significantly leaner during the first 6 months than 
breast milk or cow milk fed as indicated by greater total free 
fat mass.
The Andres study (7) was a longitudinal study over 12 months 
to assess developmental status in healthy infants enrolled in 
the Beginnings Study between 2002 and 2010 and fed breast 
milk versus cow’s milk formula versus SIF during the first year 
of life. The population included 391 infants aged 1  year, both 
male and female. The ethnicity was 91% Caucasian, 4% African-
American, and 5% others. The SES was 45.6 (10.6)–49.8 (11.0) 
on the Hollingshead scale. Exclusion criteria included a change 
of formula after 2 months of age and before 12 months, com-
plementary foods before 4 months and/or body weight <5 kg 
at 3 months. Diet decisions were made before enrollment in the 
study. Healthy infants were assessed longitudinally at ages 3, 6, 
9, and 12  months using Bayley Scales of Infant Development 
and the Preschool Language Scale-3. Mixed-effects models were 
used for statistical analyses to adjust for SES, mother’s age and 
intelligence quotient, gestational age, gender, birth weight, head 
circumference, race, age, and diet history. The independent 
variable was choice of formula, and the dependent variables 
were developmental status and anthropometric measures. The 
outcome was that infants fed SIF scored within normal limits 
on standardized developmental testing and did not differ from 
infants fed cow milk-based formula. Breast-fed infants had 
a slight advantage on cognitive development compared with 
formula fed.
The Lowe study (10) was a single-blind (patient) randomized 
control trial over a 7-year period comparing allergic outcomes 
between infants fed a conventional cow’s milk formula, a partially 
hydrolyzed whey formula, and SIF. The population included 620 
male and female infants who were enrolled before birth and had 
a family history of allergic disease. Mothers were encouraged 
to initiate and maintain breast-feeding for at least 6  months. 
Study formulas were introduced at cessation of breast-feeding. 
Skin prick tests to six common allergens were performed at 6, 
12, and 24 months. The independent variable was formula type 
(partially hydrolyzed whey formula versus soy versus casein), 
and the dependent variables were allergic manifestations (eczema 
and food reactions). The outcome was there was no evidence that 
infants randomized to the partially hydrolyzed whey formula 
or SIF were at lower risk of allergic manifestations in infancy 
compared to conventional formula. The primary outcome was 
allergic manifestation. The secondary outcomes were individual 
incidence of eczema and food reactions reported in the first 
2  years; skin prick test reactivity at 6, 12, and 24  months; and 
prevalence of eczema, asthma, and allergic rhinitis in the first 
2 years as well as at ages 6 and 7 years.
4Westmark Therapeutic Infant Formulas
Frontiers in Nutrition | www.frontiersin.org January 2017 | Volume 3 | Article 59
The Terracciano study (14) was a randomized trial to increase 
cow milk tolerance in CMA infants by treating with hydrolyzed 
rice formula or extensively hydrolyzed soy formula. Male and 
female infants aged 14.1 ± 8.6 months (n = 72) were studied over 
26 months. The independent variable was diet (rice versus soy 
versus cow milk diets), and the dependent variable was toler-
ance to CMA. This was an intention-to-treat, randomized study. 
The symptomatic formula patients from the Milan Cow’s Milk 
Allergy Cohort were randomly switched to treatment groups 
(hydrolyzed rice formula, EHCF, and extensively hydrolyzed soy 
formula). Oral food challenges were conducted with follow-up 
visits every 3 months. Statistics included Kaplan–Meier curves 
after stratification for dietary option. The Cox model was used 
to estimate hazard ratios. The outcome was 51 children reached 
tolerance at a mean of 34.1 ±  15.2  months. Both rice and soy 
diets reduced the duration of CMA. In children who were not 
co-sensitized to soy, the duration of CMA was more strongly 
impacted by diet.
The Chen study (15) examined the effects of formula feeding 
relative to breast-feeding on bone in the neonate pig. Male and 
female newborn pigs (n = 30) were studied for 21 and 35 days. 
The independent variable was diet (SIF versus cow milk-based 
formula), and the dependent variables were bone mineral density 
and bone markers. The study employed peripheral quantitative 
computed tomography scans and histomorphometric analysis. 
The outcome was piglets fed either soy- or cow milk-based 
formula had greater bone mineral density than those breast-fed. 
Osteoblast numbers and bone formation rate were greater at 
postnatal day 35 (P35) with SIF. Osteoclast numbers were lower 
in both cow milk based and SIF fed than in breast-fed subjects. 
Bone formation markers were greater and bone resorption 
markers were lower in cow milk and soy groups than in the 
breast-fed. Formula feeding promoted bone growth compared 
with breast-fed.
The Pivik study (17) evaluated variations in resting heart rate 
measures during the first half-year of life in healthy, full-term 
infants who were either breast-fed, fed milk-based formula, or fed 
SIF ± docosahexanenoic acid (DHA) supplementation. The study 
population was drawn from the Beginning Study and included 
64 male infants aged 2  months. The educational levels were 
given for both parents and were the lowest in mothers using SIF 
without DHA. The independent variable was formula type, and 
the dependent variables were anthropometrics and heart rate. 
Infants remained on parent-selected formula throughout study. 
Four diet groups included breast-fed (n =  20), milk formula 
(n = 21), SIF with DHA (n = 16), and SIF without DHA (n = 7). 
The outcome was DHA-deficient SIF resulted in higher heart rate 
and lower values for heart rate variability measures indicating 
decreased parasympathetic tone. Effects appeared at 4  months 
and continued for the remainder of study period. Later work by 
the same group found vaginal tone stability between infancy and 
2 years emerged later in SIF-fed infants compared to breast and 
cow milk formula fed (29).
The Berseth study (18) was a multicenter (20 sites), double-
blind, randomized, parallel, prospective 28-day feeding trial 
assessing body weight, infant formula tolerance and fussiness/
gas/spit-up/crying in response to SIF and partially hydrolyzed 
formula. The study population included 159 fussy, male and 
female infants aged 7–63 days. The independent variable was diet, 
and the dependent variables were fussiness, crying, gas, spit-up, 
bowel movements and consistency, diarrhea, constipation, and 
results of the Infant Characteristic Questionnaire. Subjects 
were randomized to receive SIF or partially hydrolyzed formula 
with cow milk protein/low lactose. Measurements included 
body weight and infant formula tolerance. The outcome was a 
significant reduction in mean scores of fussiness, gas, spit-up, and 
crying compared to baseline in infants receiving soy or partially 
hydrolyzed formula within 1 day of formula intake. The improve-
ment in symptoms remained constant through day 28. The soy 
group had firmer stools. Partially hydrolyzed formula, which has 
a protein profile closer to breast milk, improved formula intoler-
ance as well as SIF.
The Agostoni study (22) investigated whether the type of milk 
in the complementary feeding period (6–12 months of age) was 
associated with growth. The study population included 160 male 
and female infants aged 6–12  months with immunoglobulin E 
(IgE)-mediated CMA and breast-fed for at least 4 months with 
progressive weaning in the 5- to 6-month period. The study 
length was 12 months. Subjects were randomly assigned to one 
of three special formulas versus controls that were breast-fed up 
to 12 months. Weight for age, length for age, and weight for length 
z-scores were measured at 6, 9, and 12 months of age. Standard 
statistical methods were used including ANOVA, chi-squared, 
and Fisher tests. The independent variable was formula type (soy, 
casein hydrolyzate, rice hydrolyzate), and the dependent variables 
were growth parameters. The outcome was impaired growth at 
6 months of age in infants with CMA. The infants fed hydrolyzed 
products exhibited a trend for higher weight for age scores in the 
6- to 12-month period.
In summary, infant formula can be switched for many reasons 
such as intolerance, food allergies, fussiness, and regurgitation. 
Findings from individual RCT indicate that SIF (1) does not 
induce tolerance to cow milk protein as quickly as EHCF and 
EHCF + L. rhamnosus GG, (2) alters growth metrics such that 
infants are leaner during the first 6 months with higher BMC at 
12  months, and (3) does not affect cognitive ability in healthy 
infants. The period chosen for this data analysis (2005–2016) 
occurred after many manufacturing, supplementation, and 
agricultural practices were altered that could affect the nutrient 
content and bioactivity of SIF (Figure  1), and thus confound 
comparisons with earlier studies.
siF rCt Literature review 1985–1994
Next, we searched PubMed with the keywords “Soy” AND 
“Infant” AND “Formula” and the filters “From 1985/01/01 to 
1994/12/31” AND “Clinical Trial” and retrieved 52 citations 
(Table 2). This search was performed to enable comparison of 
cohorts consuming SIF before and after 1994 when genetically 
modified (GM) soy was introduced into the United States food 
supply. Six relevant trials published between 1985 and 1994 are 
now reviewed.
The Rigo study (33) was a prospective evaluation of the effects 
of protein hydrolyzate formulas, both whey and soy, on infant 
growth metrics during the first month of life. The population 
FiGUre 1 | History of soy-based infant formula (siF). SIFs were first 
used in the United States in 1909 and were based on soy flour. Since then, 
SIFs have undergone multiple refinements. In 1959, SIFs were supplemented 
with iodine to prevent goiter. In the 1960s, soy flour was replaced with soy 
protein isolate to ease digestion and formulate a more balanced and higher 
concentration of essential amino acids. In the 1970s, SIFs were fortified with 
methionine, carnitine, taurine, choline, and inositol. In 1994, genetically 
modified soybeans were approved for agriculture in the United States. And 
about the year 2000, SIF were supplemented with long-chain 
polyunsaturated fatty acids.
taBLe 2 | pubMed literature search with keywords “soy” and “infant” and “Formula” and filters “From 1985/01/01 to 1994/12/31” and “Clinical trial.”
1. Iron bioavailability studied in infants: the influence of phytic acid and ascorbic acid in infant formulas based on soy isolate Davidsson et al. (30)
2. Essential fatty acid metabolism and requirements for LBW infants Uauy-Dagach et al. (31)
3. Comparison of a rice-based, mixed diet versus a lactose-free, soy protein isolate formula in young children with acute diarrhea Maulen-Radovan et al. (32)
4. Nutritional evaluation of various protein hydrolyzate formulas in term infants during the first month of life Rigo et al. (33)
5. Evaluation of a maize-cowpea-palm oil diet for the dietary management of Nigerian children with acute, watery diarrhea Grange et al. (34)
6. Antigen-reduced infant formulas versus human milk: growth and metabolic parameters in the first 6 months of life Giovannini et al. (35)
7. Growth and protein status of term infants fed soy protein formulas differing in protein content Churella et al. (36)
8. Effect of dietary fat on cardiovascular risk factors in infancy Fuchs et al. (37)
9. Does early diet have an effect on subsequent macromolecular absorption and serum immunoglobulin E? Juvonen et al. (38)
10. Safety and efficacy of omega-3 fatty acids in the nutrition of very-low-birth-weight infants: soy oil and marine oil supplementation of 
formula
Uauy et al. (39)
11. Dietary modifications versus dicyclomine hydrochloride in the treatment of severe infantile colics Oggero et al. (40)
12. Cow’s milk versus soy-based formula in mild and moderate diarrhea: a randomized, controlled trial Allen et al. (41)
13. Effects of infant nutrition on cholesterol synthesis rates Cruz et al. (42)
14. Nutrient absorption and weight gain in persistent diarrhea: comparison of a traditional rice-lentil/yogurt/milk diet with soy formula Bhutta et al. (43)
15. Influence of dietary manipulation on incidence of atopic disease in infants at risk Bardare et al. (44)
16. Effect of dietary fiber (soy polysaccharide) on the severity, duration, and nutritional outcome of acute, watery diarrhea in children Brown et al. (45)
17. Clinical evaluation of the tolerance for a soy-based special milk formula in children with cow’s milk protein intolerance/allergy Buts et al. (46)
18. Bone mineralization in the first year of life in infants fed human milk, cow milk formula, or soy-based formula Mimouni et al. (47)
19. Administration of rhesus-human reassortment tetravalent rotavirus vaccine in breast-fed infants Ceyhan et al. (48)
20. Docosahexaenoic acid status of term infants fed breast milk or infant formula containing soy oil or corn oil Ponder et al. (49)
21. Long-term prevention of allergic diseases by using protein hydrolyzate formula in at-risk infants Mallet and Henocq (50)
(Continued )
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included 97 healthy infants who were enrolled shortly after birth. 
The study population was divided into six groups of newborn 
infants fed either human milk (n =  23), three different whey 
hydrolyzate formulas (#1, n = 13; #2, n = 10; #3, n = 13), soy-
collagen hydrolyzate formula (n =  18), or whey–casein hydro-
lyzate formula (n =  20). If the mothers indicated an intent to 
breast-feed, infants were assigned to the human milk group. The 
remaining infants were assigned to a hydrolyzate formula groups. 
Anthropometric data were collected at birth and at the end of the 
first month of life. The independent variable was human milk or 
type of formula, and the dependent variables were growth param-
eters, biochemical indices of protein metabolism, and plasma 
amino acid concentrations. The outcome was soy-collagen hydro-
lyzate formula, which was associated with a significant decrease 
in weight and length as well as total serum protein and transferrin 
levels compared to the human milk cohort. Immunoglobulin G 
levels were significantly increased compared to the breast-fed 
cohort. Soy-collagen hydrolyzate formula led to an increase in 
several amino acids including glycine, hydroxyproline, citrulline, 
ornithine, arginine, aspartic acid, serine, threonine, and histidine 
as well as a decrease in lysine and cystine. Whey–casein hydrolyz-
ate formula induced a plasma amino acid pattern closer to the 
human milk profile. Of note, the use of soy-collagen hydrolyzate 
22. Bone mineral metabolism in full-term infants fed human milk, cow milk-based, and soy-based formulas Venkataraman et al. (51)
23. Gastric emptying using three different formulas in infants with gastroesophageal reflux Tolia et al. (52)
24. Dietary essential fatty acid supply and visual acuity development Birch et al. (53)
25. Nutritional management of persistent diarrhea: factors predicting clinical outcome Bhutta et al. (54)
26. Retinal development in very-low-birth-weight infants fed diets differing in omega-3 fatty acids Birch et al. (55)
27. Modulation of infant formula fat profile alters the low-density lipoprotein/high-density lipoprotein ratio and plasma fatty acid 
distribution relative to those with breast-feeding
Hayes et al. (56)
28. Tolerance of a soy formula by infants and children Nadasdi (57)
29. Dietary management of persistent diarrhea: comparison of a traditional rice-lentil based diet with soy formula Bhutta et al. (58)
30. Evaluation of the effect of a fiber-enriched formula on infant colic Treem et al. (59)
31. Cumulative incidence of atopic disorders in high-risk infants fed whey hydrolyzate, soy, and conventional cow milk formulas Chandra and Hamed (60)
32. Role of a soy-based lactose-free formula in the outpatient management of diarrhea Santosham et al. (61)
33. Safety of casein hydrolyzate formula in children with cow milk allergy Sampson et al. (62)
34. Evaluation of a new Israel infant soy formula Weizman (63)
35. Clinical trial of home available, mixed diets versus a lactose-free, soy protein formula for the dietary management of acute 
childhood diarrhea
Alarcon et al. (64)
36. Role of carnitine in utilization of dietary medium-chain triglycerides by term infants Rebouche et al. (65)
37. Absorption and retention in acute diarrhea Mann et al. (66)
38. Enteral nutrition in infants with congenital heart disease and growth failure Schwarz et al. (67)
39. A comparison of rice-based oral rehydration solution and “early feeding” for the treatment of acute diarrhea in infants Santosham et al. (68)
40. Effects of unrestricted diet on mild infantile diarrhea. A practice-based study Margolis et al. (69)
41. Colic and the effect of changing formulas: a double-blind, multiple-crossover study Forsyth (70)
42. Response to RIT 4,237 oral rotavirus vaccine in human milk, adapted- and soy formula-fed infants Zoppi et al. (71)
43. Oral refeeding following acute gastroenteritis: a clinical trial using four refeeding regimes Quak et al. (72)
44. Effect of feeding whey hydrolyzate, soy, and conventional cow milk formulas on incidence of atopic disease in high-risk infants Chandra et al. (73)
45. Influence of maternal diet during lactation and use of formula feeds on development of atopic eczema in high-risk infants Chandra et al. (73)
46. Low carnitine intake and altered lipid metabolism in infants Olson et al. (74)
47. Parental counseling compared with elimination of cow’s milk or soy milk protein for the treatment of infant colic syndrome: a 
randomized trial
Taubman (75)
48. The effect of feeding four different formulas on stool weights in prolonged dehydrating infantile gastroenteritis Rajah et al. (76)
49. Chronic diarrhea and soy formulas. Inhibition of diarrhea by lactose Donovan and Torres-
Pinedo (77)
50. Bone mineralization and growth in term infants fed soy-based or cow milk-based formula Steichen and Tsang (78)
51. Role of soy-based, lactose-free formula during treatment of acute diarrhea Santosham et al. (79)
52. Protein quality and quantity in preterm infants receiving the same energy intake Darling et al. (80)
taBLe 2 | Continued
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formula makes it difficult to ascertain the effects of soy compared 
to the collagen.
The Giovannini study (35) was a prospective evaluation of 
growth and metabolic parameters in infants during the first 
6 months of life in response to formula type. The study popula-
tion included 82 infants with a family history of IgE-mediated 
disease. Infants were divided according to the type of milk feed-
ing from the end of the first month of life up to 6 months: human 
milk (n = 29), SIF (n = 15), whey-based low-degree hydrolyzate 
(n = 15), casein-based high-degree hydrolyzate (n = 13), and soy 
plus collagen-based high-degree hydrolyzate (n =  10). At 0, 3, 
and 6 months of life, anthropometric measurements were taken. 
A fasting blood sample was obtained at 5 months of age before 
beginning introduction of solid foods. The independent variable 
was human milk or type of formula, and the dependent vari-
ables were anthropometric measures (weight, length, and head 
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circumference) and biochemical parameters (serum hemoglobin, 
blood urea nitrogen, glucose, calcium, phosphorus, alkaline 
phosphatase, and transferrin). The outcome was a lower body 
mass index and higher blood urea nitrogen in the casein-based 
high-degree hydrolyzate group at 3 months and higher levels of 
essential amino acids in soy formula, whey-based low-degree 
hydrolyzate, and casein-based high-degree hydrolyzate groups. 
There were lower levels of branched-chain amino acids in all 
formula-fed infants compared to breast-fed.
The Churella study (36) was a blind, parallel RCT that measured 
growth and protein status in full-term infants fed SIF with vary-
ing protein concentration. The Abbott Laboratories-sponsored 
study enrolled 84 infants at 2 days of age who were free of genetic 
abnormalities and had no signs of cardiac, respiratory, gastro-
intestinal, or metabolic disease. Infants were randomly assigned 
formula that was the single food source until 112 days of age in 
a blind parallel study. Subjects, n = 20, were removed during the 
study for suspected formula intolerance, illness not related to the 
formula, poor growth due to gastroesophageal reflux, parents did 
not return infant for clinic visits, parents removed infant from 
study, or infant received other than the assigned feeding. The final 
analysis included 32 male and 32 female infants. The independent 
variable was type of formula (normal or lower soy protein), and 
the dependent variables were anthropometric (weight, length, 
and head circumference), plasma biomarkers (plasma urea nitro-
gen, total protein albumin, and transthyretin), and stool charac-
teristics. The outcome was no statistically significant differences 
in weight, length, or head circumference. Plasma urea nitrogen 
levels were lower in infants fed the lower protein SIF. The other 
plasma measurements, tolerance to the two formulas and stool 
characteristics, were similar. Unfortunately, there was no non-soy 
control group for comparison. The widely used Enfamil ProSobee 
contains 2.5 g soy protein per 100 kcal of formula (Figure S1 in 
Supplementary Material), which is similar to the protein content 
of the lower soy protein formula employed in this study (2.45 g 
protein per 100 kcal).
The Mimouni study (47) was a single-blind, prospective trial 
evaluating bone mineralization in healthy infants fed human 
milk versus cow milk formula (Similac) or SIF (Isomil or 
ProSobee). All infants were selected from a population in which 
the mothers elected not to breast-feed. Breast-fed infants were 
recruited concurrently for comparison. Parents were aware of the 
formula assignments, but investigators taking the measurements 
were blind. Infants (n =  107) were enrolled with 59 complet-
ing the study through week 52 and 72 completing the study 
through week 16. The 72 infants completing the study through 
week 16 were included in the final analysis and consisted of 
breast-fed (n  =  10), Similac (n  =  20), Isomil (n  =  21), and 
ProSobee (n = 21). The independent variable was formula type, 
and the dependent variables were anthropometrics, BMC, and 
plasma biomarkers. Gain in length was significantly greater 
in all formula groups compared to breast-fed infants through 
week 26. The difference was no longer significant at 1  year of 
age. BMC and bone width of the radius was similar among all 
groups. There were no differences in calcium, magnesium, or 
alkaline phosphatase among groups. Serum P levels were higher 
at the 8-week follow-up in formula fed versus breast-fed. The 
ProSobee group had higher serum 1,25-dihydroxyvitamin D at 
8, 16, and 26 weeks.
The Venkataraman (51) study was a prospective assessment 
of bone mineral metabolism in full-term infants fed human milk 
versus cow milk-based or SIF. The study population included 56 
healthy, full-term infants who were assigned to formula groups 
by a random block design to achieve equal distribution of 
genders between groups: breast milk (n = 17), cow milk-based 
formula (Similac, n = 19), and SIF (Isomil, n = 20). Infants were 
exclusively fed breast milk or formula fed for first 4 months. The 
independent variable was type of milk fed, and the dependent 
variables were anthropometric measurements, plasma biomark-
ers and BMC at 8, 16, and 24–26 weeks of age. The outcome was 
growth and most plasma biomarkers in the infants did not differ 
significantly among groups. Serum phosphorus was significantly 
lower in the breast-fed group at 8 weeks of age compared to the 
cow milk formula cohort. The BMC at 16 and 24–26 weeks was 
higher in the soy cohort than the breast-fed, and bone width was 
higher at 16 weeks in the soy group.
The Steichen study (78) was a prospective evaluation of bone 
mineralization and growth in full-term infants fed SIF or cow 
milk-based formula in the first year of life. Infants (n = 36) were 
enrolled and all but one completed the study. Subjects were ran-
domly assigned to feeding groups (Isomil with iron, SIF) versus 
Similac with iron (cow milk-based) and received formula within 
24 h of birth. Nutrition for the first 6 months of life was exclu-
sively formula. The independent variable was formula type, and 
the dependent variables were anthropometrics, BMC, and bone 
widths of the radius and ulna. The outcome was no differences in 
weight, length, and head circumference among groups. The soy 
group had lower BMC at 3, 6, 9, and 12 months of age but values 
were similar to those in previously studied breast-fed infants with 
vitamin D supplementation.
Of note, growth metrics are the most widely used indicator of 
infant health. The few RCT that have examined the effects of SIF 
on growth metrics have been in healthy, full-term infants and 
differences have not been observed. There were two published 
studies that included anthropometric data on height, weight, 
and head circumference in response to breast milk versus cow 
milk based or SIF that performed measurements at similar ages. 
Both studies were conducted in the United States. One study 
was published in 1992 and the other in 2012 allowing for the 
comparison of Generation Y (the millennial generation) versus 
Generation Z (the digital generation) at 6  months of age. We 
compared their results to determine if there was any change in 
infant anthropometric measurements between generations in 
response to consumption of SIF pre- and post-1994 when GM 
soybeans were introduced into farming. There appear to be no 
statistically significant changes in height, weight, or head circum-
ference at birth or after 6 months with respect to diet (Table 3). 
The Venkataraman study enrolled full-term, healthy infants 
delivered at the Oklahoma Memorial Hospital in Oklahoma 
City between October 1986 and August 1990 (51). The Andres 
study enrolled participants from the Beginnings Study between 
2002 and 2010 at the Arkansas Children’s Nutrition Center (7). 
In  both studies, complementary foods were not introduced 
before 4 months of age.
taBLe 3 | Comparison of infant growth metrics in response to soy-based infant formula, Generation y versus Generation Z.
study Generation y (51) Generation Z (7)
diet base Breast 
n = 17
Cow 
n = 19
soy 
n = 20
Breast 
n = 131
Cow  
n = 131
soy 
n = 129
at birth
Weight (kg) 3.37 ± 0.0 3.27 ± 0.09 3.35 ± 0.07 3.58 ± 0.34 3.51 ± 0.39 3.45 ± 0.37
Height (cm) 51 ± 0.6 50.8 ± 0.5 51.2 ± 0.6 51.6 ± 2.2 51.3 ± 2.5 51.2 ± 2.2
Head circumference (cm) 34.9 ± 0.3 34.2 ± 0.3 34.4 ± 0.4 ND ND ND
at 6 months
Weight (kg) 7.4 ± 0.2 7.5 ± 0.2 7.9 ± 0.3 7.7 ± 0.9 8.0 ± 0.8 7.9 ± 0.8
Height (cm) 66.9 ± 0.9 66.6 ± 0.7 67.2 ± 1.0 66.2 ± 2.4 66.7 ± 2.3 66.6 ± 2.2
Head circumference (cm) 43.9 ± 0.3 43.7 ± 0.3 43.4 ± 0.5 43.5 ± 1.3 43.6 ± 0.2 43.8 ± 1.3
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siF systematic and Meta-analysis 
Literature review
In addition to the reviewed RCT, there has been one systematic 
review with meta-analysis entitled, “Safety of soya-based infant 
formulas in children” (81). The authors reviewed the safety of 
SIF in relation to anthropometric growth, BMC, immunity, 
cognition, and reproduction and endocrine function. The 
search strategy identified 156 potential studies published 
between 1909 and 2013 with 121 articles eliminated because 
they either covered non-related topics, were reviews, or did 
not contain sufficient extractable data. Studies were grouped 
based on pre- (11 studies published between 1960 and 1987) 
and post-fortification (11 studies published between 1992 and 
2013) of SIF. The authors concluded, “Modern soy-based infant 
formulas are evidence-based safety options to feed children 
requiring them. The patterns of growth, bone health and 
metabolic, reproductive, endocrine, immune and neurological 
functions are similar to those observed in children fed cow milk 
formula or human milk.” Another extensive review of the SIF 
literature was conducted by an expert panel recruited by the 
National Toxicology Program Center for the Evaluation of Risks 
to Human Reproduction, which reviewed 28 published human 
studies and more than 120 laboratory animal studies that were 
considered to have utility for the safety evaluation of SIF (82). 
Overall, the panel recommended there was, “minimal concern 
for adverse effects on development in infants who consume 
soy infant formula.”
soy-associated Health Benefits
The second argument in favor of developing therapeutic SIF 
is that soy protein is associated with health benefits in adults. 
The United States Food and Drug Administration (FDA) allows 
products with at least 6.25 g of soy protein to carry the health 
claim that they, “may help to lower the risk of cardiovascular 
disease.” The strength of the evidence to support this claim comes 
from an Evidence Analysis Library review in March of 2004 of 
studies regarding the effect of soy protein (26–50 g/day) on cho-
lesterol levels in subjects with normal and elevated cholesterol 
(total cholesterol >200 mg/dL) and in subjects with diabetes. The 
review found that total serum cholesterol was reduced 0–20%, 
triglycerides were reduced 0–22%, and low-density lipoprotein 
(LDL) was reduced 4–24%. The overall strength of the evidence 
was given a Grade II (fair) and based on one high-quality meta-
analysis plus two high-quality and two neutral-quality RCT 
that reported lower total cholesterol or LDL or both in adults 
who consumed at least 26 g of soy protein per day. There was 
one neutral-quality RCT that showed reduced high-density 
lipoprotein (HDL). Non-supporting studies included one high-
quality meta-analysis and one high-quality RCT that found 
no soy-dependent differences in total cholesterol or LDL. The 
supporting high-quality meta-analysis included 38 controlled 
clinical trials on the effects of soy protein intake on serum lipids 
and indicated that the consumption of soy protein (average 
intake 47 g/day) instead of animal protein was associated with 
a decrease of 23.2 mg/dL (9.3%) in total cholesterol, 21.7 mg/dL 
(12.9%) in LDL, and 13.3 mg/dL (10.5%) in triglycerides (83). 
The Evidence Analysis Library also found that the effect of soy 
protein and/or isoflavones on total cholesterol, LDL, and HDL 
may vary based on baseline cholesterol levels and that there is 
no dose–response relationship between isoflavone consumption 
levels and effects on cholesterol. The Evidence Analysis Library 
recommends, “If consistent with patient preference and not con-
traindicated by risk/harms, then soy (e.g., isolated soy protein, 
textured soy, tofu) may be included as part of a cardioprotec-
tive diet. Consuming 26–50 g of soy protein per day in place of 
animal protein can reduce total cholesterol by 0–20% and LDL 
by 4–24%. Evidence is insufficient to establish a beneficial role of 
isoflavones as an independent component.”
In addition to reviewing available data on cholesterol effects, 
the Evidence Analysis Library reviewed nine RCT on the effect of 
soy (18–40 g/day) or isoflavone (70–143 mg/day) intake on blood 
pressure and found no effect in four trials, an increase in systolic 
blood pressure in women in one trial, and a decrease in systolic 
(4.3–18.4 mmHg) and diastolic (2.8–15.9 mmHg) blood pressure 
in four trials. They advise that, “the consumption of soy foods 
may or may not be beneficial for the reduction of blood pressure, 
since the effect of increased soy food intake on blood pressure is 
unclear.” They have determined that up to 30 g/day of soy protein 
consumed as supplements in the diet is well tolerated. Caveats are 
that soy may be an allergen, may not be recommended in those 
with or at high risk for breast cancer, and levels greater than 50 g/
day may cause gastrointestinal distress.
Subsequent to the Evidence Analysis Library study, a meta-
analysis found improved LDL, HDL, and fasting triacylglycerol 
levels suggesting that daily consumption of 15–30  g of soy 
taBLe 4 | Macro- and micronutrient content of soy protein isolate 
(1986–2013).
proximates Level (per 100 g)
Water (g) 4.98
Energy (kcal) 338
Protein (g) 80.69
Total lipid (g) 3.39
Carbohydrate (g) 7.36
Fiber (total dietary)a (g) 5.6
Total sugarsb (g) 0
Ash (g) 3.58
Minerals Level (per 100 g)
Calcium (mg) 178
Iron (mg) 14.5
Magnesium (mg) 39
Phosphorus (mg) 776
Potassium (mg) 81
Sodium (mg) 1,005
Zinc (mg) 4.03
Copper (mg) 1.599
Manganese (mg) 1.493
Seleniumc (mg) 0.8
Vitamins Level (per 100 g)
Vitamin C (mg) 0
Thiamin (mg) 0.176
Riboflavin (mg) 0.1
Niacin (mg) 1.438
Vitamin B5 (mg) 0.06
Vitamin B6a (mg) 0.1
Folate (mg) 176
Vitamin B12 (mg) 0
Vitamin A (IU) 0
Vitamin Ed (mg) 0
Vitamin De (IU) 0
Vitamin Kb (mg) 0
Choline (total)f (mg) 190.9
Lipids Level (per 100 g)
Fatty acids (total saturated) (g) 0.422
Fatty acids (total monounsaturated) (g) 0.645
Fatty acids (total polyunsaturated) (g) 1.648
Cholesterol (mg) 0
Data available from a1997–2013, b2004–2013, c1998–2013, d2000–2013, e2009–2013, 
f2008–2013.
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significantly improved serum risk factors for cardiovascular 
disease (84). A meta-analysis of soy product consumption in 
patients with type 2 diabetes mellitus found that soy protein 
intake was beneficial in diabetic patients in terms of serum lipids, 
but there were no significant effects on fasting glucose, insulin, 
or glycated hemoglobin levels (85). In addition, consumption of 
soy or soy isoflavones is associated with reduced prostate cancer 
(86–89), gynecological cancers (90), and possibly breast cancer 
(91–96). Soy isoflavones stimulate bone formation, inhibit bone 
resorption, and increase bone mineral density resulting in attenu-
ation of bone loss in menopausal women (97–101), albeit there 
are reports of only slight or no clinical effects (102).
Biological and economical advantages 
of a siF drug delivery platform
The third argument in support of therapeutic SIF is that soybeans 
are an economical means to generate and deliver therapeutics. 
According to the American Soybean Association, soybeans 
were the second largest cash crop in the United States in 2012. 
Soybeans can be transfected with therapeutic genes of inter-
est by biolistic gene delivery and then the soybeans produce 
the coded for proteins, which can be delivered to patients in a 
soymilk platform. Soy is the only plant protein source contain-
ing a complete amino acid profile. To determine if there was an 
association between the introduction of GM soybeans and the 
macro- and micronutrient content of soy protein, we analyzed 
data available from the United States Department of Agriculture 
National Nutrient Database for Standard Reference,1,2 which 
is the major source for food composition data in the United 
States. Release 26 (November, 2013) contains nutrient data for 
8,463 food items and up to 150 food components. An analysis 
of the nutrient composition of soy protein isolate, the protein 
source in SIF, indicates that the proximate, mineral, vitamin, and 
lipid content of soy protein isolate have not changed from 1986 
to 2013 (Table 4) GM soy was introduced into the food supply 
in the United States in 1995 and has currently grown to greater 
than 90% of soy production. Although not a controlled study, 
the non-variability in macro- and micronutrient content in soy 
protein isolate between 1986 and 2013 suggests that the genetic 
modification of soybeans has not altered these parameters.
tHe Case aGainst soy-Based 
tHerapeUtiC inFant ForMULas
The major argument opposing the use of SIF and therapeutic SIF 
is that safety has not been rigorously tested, particularly potential 
health effects associated with phytoestrogens, agrochemicals, 
and GM components. While the expert panel for the National 
Toxicology Program Center for the Evaluation of Risks to Human 
Reproduction concluded that there was minimal concern for 
adverse effects on development in infants consuming SIF, the 
1 United States Department of Agriculture (2013) USDA National Nutrient 
Database for Standard Reference, release 26, http://www.ars.usda.gov/Services/
docs.htm?docid=8964.
2 United States Department of Agriculture (1986) USDA Agriculture Handbook.
decision was not unanimous (82). There was a dissenting opinion 
that: “(1) There are sufficient signals of adverse reproductive and 
developmental effects in experimental animals to worry about 
long-term effects on development of infants; (2) infants are exqui-
sitely sensitive to the effects of exogenous chemicals during early 
life, and naturally occurring genistein in SIF has a much stronger 
estrogenic effect than non-natural estrogenic compounds on the 
developing reproductive system; and (3) the absence of evidence 
of an effect in human studies is not the same as evidence of absence 
of an effect, particularly given the paucity of human data to inform 
the conclusion.” Of the recent SIF RCT reviewed above, only four 
studies were longitudinal and only one assessed cognition. None 
of the studies assessed neurological outcomes or potential effects 
of agrochemicals, nor did they compare SIF versus GM SIF. All 
taBLe 5 | summary of Cochrane database reports with keyword “soy.”
1. Alternative lipid emulsions versus pure soy oil-based lipid emulsions for parenterally fed preterm infants (Review)
P: Preterm infants (<37 weeks gestation) who received intravenous lipid emulsions as a part either of total parenteral nutrition 
or partial parenteral nutrition within the first week of life and for a minimum of 5 days
I: S-LE
C: Compare the effects of S-LE versus medium-chain triglyceride/long-chain triglycerides (MCT/LCT) LE, MCT-olive-fish-soy oil LE 
(MOFS-LE), MCT-fish-soy-oil LE (MFS-LE), olive-soy oil LE (OS-LE), borage-soy oil LE (BS-LE) on death, physical growth, chronic 
lung disease, and long-term neurodevelopmental outcomes
O: There was a pooled effect toward decreased bronchopulmonary dysplasia (BPD) in OS-LE versus S-LE not reaching statistical 
significance. No difference in BPD was observed in any other comparison. There were no statistically significant differences in the 
primary outcomes of death, growth rate, or days to regain birth weight in any comparison
Kapoor et al. (107), 
Issue 12
2. Lifestyle interventions for the treatment of urinary incontinence in adults (Review)
P: Adults with urinary incontinence
I: Weight loss, diet (soy-rich versus soy-free), fluid intake, reducing caffeine intake
C: Compared lifestyle interventions for the treatment of urinary incontinence
O: There is insufficient evidence to inform practice regarding the effectiveness of lifestyle interventions albeit available data show that 
evidence is growing for weight loss as a treatment to reduce urinary incontinence among morbidly and moderately obese women
Imamura et al. (108), 
Issue 12
3. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein, and dietary fibers) for familial hypercholesterolemia 
(Review)
P: Children and adults with familial hypercholesterolemia
I: Omega-3 fatty acids, soya proteins, plant sterols, or plant stanols
C: Compared efficacy of cholesterol-lowering diet in reducing ischemic heart disease and lowering cholesterol with no dietary 
intervention and with supplements
O: No conclusions could be made regarding effectiveness of a cholesterol-lowering diet or any other dietary interventions for familial 
hypercholesterolemia in regard to incidence of ischemic heart disease, number of deaths, and age at death
Malhotra et al. (109), 
Issue 6
4. Phytoestrogens for menopause vasomotor systems (Review)
P: Peri- and postmenopausal women without a history of breast cancer
I: Soy phytoestrogens
C: Compared the efficacy, safety, and acceptability of food products, extracts and dietary supplements containing high levels of 
phytoestrogens with no treatment, placebo, or hormone therapy
O: There was a strong placebo effect, no conclusive evidence that phytoestrogen supplements were effective in reducing the severity 
or frequency of vasomoter symptoms associated with menopause, and four individual studies that could not be combined for meta-
analysis but that suggested genistein extracts at greater than 30 mg/day reduce the frequency of hot flushes
Lethaby et al. (110), 
Issue 12
5. Specially formulated foods for treating children with moderate acute malnutrition in low- and middle-income countries (Review)
P: Children between 6 months and 5 years of age in low- and middle-income countries with MAM
I: Specially formulated foods: LNS versus blended foods. LNS are food with high energy density and high lipid content. Blended 
foods are dry mixtures without high lipid content that can be cooked at home to make porridge or soup
Lazzerini et al. (111), 
Issue 6
C: Compare the effectiveness and safety of specially formulated foods with standard care (medical care without foods)
(Continued )
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of the studies were conducted in healthy full-term infants, but 
infants genetically predisposed to developmental disabilities may 
be more susceptible to adverse chemical effects.
In general, the literature contains many conflicting reports 
regarding the health benefits of consuming soy and phytoes-
trogen supplements. The FDA recommends that 25 g per day of 
soy protein, as part of a diet low in saturated fat and cholesterol, 
may reduce the risk of heart disease. However, a review of 22 
RCT comparing soy protein isolate to milk and other proteins 
on LDL cholesterol levels by the Nutrition Committee of the 
American Heart Association found that the average effect was 
only 3% (103). There was no benefit regarding HDL, triglycer-
ides, or blood pressure. There is no conclusive evidence that soy 
phytoestrogens reduce hot flashes associated with menopause 
(91–96). In addition to the RCT and Evidence Analysis Library 
literature, a database search of the Cochrane Library with the 
keyword “Soy” retrieved 10 reviews and one protocol report, 
which are summarized in Table  5. Overall, these systematic 
and/or meta-analysis reports found no conclusive evidence 
supporting improved health with soy in terms of vasomotor 
effects in menopause, cholesterol levels in hypercholesterolemia, 
or allergies in infancy and childhood. There were limited data 
that genistein extracts may reduce hot flushes. There were no 
systematic reviews in the Cochrane Library regarding infant 
growth metrics in relation to soy. We did not observe a difference 
in growth metrics with SIF (Table 3), but there was only one 1992 
and one 2012 study for comparison. A recent systematic review 
comparing milk-based formulas and SIF concluded that SIF are 
likely more carcinogenic; however, the evidence was limited 
(104). A study of isoflavone pharmacokinetics in rhesus mon-
keys indicated that metabolic and/or physiological immaturity 
in neonates reduces total clearance of soy isoflavones (105). Of 
note, although the FDA authorized a health claim linking the 
consumption of soy protein with reduced risk of coronary heart 
disease, the agency also lists soy in its Poisonous Plant Database 
with warnings regarding goiter, growth problems, amino acid 
deficiencies, mineral malabsorption, endocrine disruption, and 
carcinogenesis (106).
O: There was moderate to high-quality evidence that both LNS and blended foods are effective in treating MAM. There was no 
difference between LNS and blended foods in terms of number of deaths, progression to severe acute malnutrition, or drop out rate. 
LNS increased the number of recoveries and slightly improved nutritional status among those recovered
Note: This study was retrieved during the search of the Cochrane database because soy was a component of the LNS and blended food
6. Isoflavones for hypercholesterolemia in adults (Review)
P: Hypercholesterolaemic postmenopausal women ranging in age from 40 to 83 years
I: Isoflavones or SPI containing isoflavones
C: Compared isoflavones versus placebo. Compared SPI plus isoflavones versus SPI alone
O: There was no evidence that isoflavones affected total cholesterol, LDL, or HDL. There was a small statistically significant decrease 
in triglycerides with isoflavones alone but not with SPI
Qin et al. (112),  
Issue 6
7. Polyunsaturated fatty acid (PUFA) supplementation in infancy for the prevention of allergy and food hypersensitivity (Protocol)
P: Infants (cohorts fed: breast milk, cow milk formula, soy formula fed, hydrolyzed formula, complementary feeding) in their first year 
of life without clinical evidence of allergic disease at time of enrollment
I: PUFA supplements
C: Compare the effect of PUFAs in healthy, low risk, and high risk for allergy and food hypersensitivity infants. Compare the effect of 
PUFAs in low birth weight, preterm, and term infants.
O: N/A: this was a Protocol study
Note: Populations that have diets with elevated omega-3 PUFAs have a lower incidence of inflammatory conditions
Schindler et al. (113), 
Issue 9
8. Probiotics for preventing acute URTI (Review)
P: Infants, children, and adults around age 40 years
I: Probiotics
C: Compare the effectiveness and safety of probiotics with placebo in preventing acute URTI
O: Meta-analysis indicated that probiotics were effective in reducing URTI and the number of associated antibiotic prescriptions, but 
there was no effect on the mean duration of an URTI episode
Note: This study was retrieved during the search of the Cochrane database because probiotics are commonly consumed in 
fermented foods including yogurt and soy yogurt
Hao et al. (114),  
Issue 9
9. Exercise for vasomotor menopausal symptoms (Review)
P: Peri- and postmenopausal women
I: Exercise
C: Compare the effectiveness of any type of exercise intervention on the management of vasomotor menopausal symptoms
O: In one small study that could not be included in the meta-analysis, hot flush scores were significantly lower in the exercise plus 
soy milk group than in the soy milk only group
Daley et al. (115),  
Issue 5
10. Formulas containing hydrolyzed protein for prevention of allergy and food intolerance in infants (Review)
P: Infants in the first 6 months of life without clinical evidence of allergy
I: Hydrolyzed protein formula
C: Compare the effect of feeding hydrolyzed protein formula to adapted cow milk or human breast milk on allergy and food 
intolerance
O: There were no significant difference in infant allergy or childhood CMA and thus no evidence to support using hydrolyzed formula 
to prevent allergy compared to exclusive breast-feeding. With high-risk infants unable to breast feed, there was limited evidence that 
prolonged feeding with hydrolyzed formula may reduce infant and childhood allergy and infant CMA compared to cow milk formula
Osborn and Sinn (116), 
Issue 4
11. Soy formula for prevention of allergy and food intolerance in infants (Review)
P: Infants in the first 6 months of life without clinical evidence of allergy or food intolerance
I: Adapted soy formula
C: Compare the effect of feeding adapted soy formula to human milk, cow milk formula, or hydrolyzed protein formula in preventing 
allergy or food intolerance
O: By meta-analysis, there were no significant difference in childhood allergy, asthma, eczema, or rhinitis
Osborn and Sinn (116), 
Issue 4
S-LE, soybean oil-based lipid emulsions; MCT/LCT, medium-chain triglyceride/long-chain triglycerides LE; MOFS-LE, MCT-olive-fish-soy oil LE; MFS-LE, MCT-fish-soy-oil LE; 
OS-LE, olive-soy oil LE; BS-LE, borage-soy oil LE; BPD, bronchopulmonary dysplasia; MAM, moderate acute malnutrition; LNS, lipid-based nutrient supplements; SPI, soy protein 
isolate; PUFA, polyunsaturated fatty acid; URTI, upper respiratory tract infections.
taBLe 5 | Continued
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soy Contains toxic substances
Soy protein isolate comprises 14–16% of SIF by weight and 
contains many potentially toxic substances including phytoes-
trogens, saponins, protease inhibitors, and phytic acid that can 
interfere with digestion, reproduction, and thyroid function 
(82, 106, 117). Soy protein is rich is phytoestrogens including 
isoflavones such as genistein and daidzein. Genistein accounts 
for greater than 65% of the isoflavone content of SIF with total 
isoflavone concentrations ranging from 32 to 47 mg/L compared 
to human breast milk at 5.6 ± 4.4 mg/L (118). Infants fed SIF 
are exposed to 22–45 mg isoflavones per day (6–11 mg per kg 
body weight per day). High steady-state plasma concentration of 
isoflavones are maintained in infants by frequent feeding. These 
circulating isoflavone concentrations are 13,000–22,000-fold 
higher than plasma estradiol concentrations in early life. Chen 
and Rogan have estimated genistein consumption from SIF in 
terms of estrogenicity at about five contraceptive pills per day 
(119). The individual and total isoflavone content in SIF from 
taBLe 6 | isoflavone content of soy protein isolate and powdered soy-
based infant formulas.
nutrient Meana N sd Min Max
soy protein isolate
Daidzein 30.81 49 12.73 7.70 68.89
Genistein 57.28 55 14.17 27.17 105.10
Glycitein 8.54 42 3.22 5.4 26.40
Total isoflavones 91.05 49 26.00 46.5 199.25
infant formula (powder)
Abbott Similac with iron
Daidzein 6.03 6 0.00 6.03 6.03
Genistein 12.23 6 0.51 11.43 13.03
Glycitein 2.73 6 0.02 2.70 2.77
Total isoflavones 25.82 11 2.85 20.17 31.60
Enfamil next step
Daidzein 7.23 4 0.06 7.15 7.30
Genistein 14.75 4 0.20 14.50 15.00
Glycitein 3.00 4 0.04 2.95 3.05
Total isoflavones 25.00 4 0.08 24.90 25.10
PBM products bright beginnings
Daidzein 5.70 2 ND 5.70 5.70
Genistein 13.55 2 ND 13.55 13.55
Glycitein 2.05 2 ND 2.05 2.05
Total isoflavones 28.01 7 2.95 21.30 30.70
amg/100 g.
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Abbott, Enfamil, and PBM Products (powder form) were similar 
(Table 6). It should be noted, though, that nutrient databases are 
limited in their ability to estimate daily isoflavone intake as total 
isoflavone content varies significantly among soy protein iso-
lates. Isoflavone content in soy products is highly variable due to 
differences in manufacturing processes (e.g., solvents, heating), 
analytical testing methods (e.g., solvents, enzymatic hydrolysis), 
and biological variability in the soybeans. Biological variability 
is the greatest variable and can be dependent on crop differences 
(e.g., growing conditions, maturity of soybeans, soybean strain, 
geographical location). Flavonoids and isoflavonoids occur 
in plants and food almost exclusively as glycosides, which are 
stable to most cooking methods, stomach acid, and secreted 
gastric enzymes (120). Deglycosylation can occur at several 
sites in the duodenum and jejunum and is a prerequisite for 
conjugation by intestinal enzymes and absorption by the small 
intestine. An analytical assessment of isoflavone content in soy 
milk and soy protein isolate over a 3-year period (1998–2000) 
indicated that isoflavone concentrations in soy protein isolate 
varied by 200–300%, but the protein content only varied by 3% 
(121). Isoflavone levels were not affected by storage of soy milk 
products for 359 days indicating that these bioactive compounds 
are highly stable; however, there is likely a two- to threefold 
variation in isoflavone content over a 6-month manufacturing 
period for any single branded soy product (121, 122). SIF in the 
United States have the highest phytoestrogen concentrations 
(genistein, daidzein, and glycitein) compared to the United 
Kingdom, Australia, New Zealand, and Brazil (82). Regarding 
the other potentially toxic chemicals in soy, saponins are soap-
like foaming chemicals that are often bitter in taste. Heating SIF 
does not completely inactive the protease inhibitors. The phytic 
acid can bind to and prevent the absorption of minerals and 
niacin; hence, formulas must be fortified with iron, calcium, 
phosphorus, magnesium, zinc, manganese, copper, iodine, 
sodium, selenium, potassium chloride, choline, and inositol as 
well as vitamins A, C, D, E, K, and B (B1, B2, B6, B12, niacin, 
folic acid, pantothenic acid, and biotin). SIF contains high levels 
of manganese and aluminum (123–125).
In addition to the potentially toxic substances found naturally 
in soy, soybeans undergo an extensive manufacturing process 
that can contaminate the soy protein with chemicals. An adver-
tisement from Crown Iron Works Company that depicts the 
extensive chemical and heating steps involved in the soybean 
manufacturing process that produces soy protein isolate is repro-
duced with permission (Figure S2 in Supplementary Material). 
The process involves washing the soybeans with hexane followed 
by heat shock. The Total Diet Study, also known as the market 
basket study, is an ongoing FDA program that determines the 
level of various contaminants and nutrients in foods.3 Samples 
were collected between September 1991 and October 2003. 
Milk-based infant formula fortified with iron contains no detect-
able pesticide residues. Milk-based infant formula with low iron 
contains an average of 0.00052  ppm benzene, 0.00132  ppm 
chloroform, 0.00005  ppm styrene, and 0.00027  ppm toluene. 
SIF contains 0.00066  ppm benzene, 0.00120  ppm chloroform, 
0.00001  ppm chlorpyrifos-methyl, 0.00005  ppm styrene, 
0.00032 ppm toluene, and 0.00007 ppm xylene (m- and/or p-). 
The most recent market baskets collected between October 
2003 and August 2005 did not include infant formula data. And 
unfortunately, the most commonly used pesticide, glyphosate, 
is not one of the contaminants tested by the Total Diet Study. 
Samsel and Seneff (126) found 170 ppb glyphosate in Enfamil 
ProSobee liquid concentrate.
Studies examining the health effects of soy are further compli-
cated by the fact that 93% of soybean crops in the United States 
are GM (127). Glyphosate-tolerant soybeans were genetically 
engineered to express the 5-enolpyruvylshikimate-3-phosphate 
synthase gene from the CP4 strain of the bacteria Agrobacterium 
tumefaciens, which infers resistance to the Roundup® herbicide 
glyphosate. Since the mid-1990s, there has been a steady 
increase in the use of GM soybeans in agriculture along with 
the concomitant use of glyphosate. Glyphosate is sprayed on GM 
crops where is acts as both a pesticide and herbicide as well as 
on other crops (for example, wheat) where it serves as a dry-
ing agent. This chemical accumulates in the soil, is not easily 
degraded, and is a known antibiotic and endocrine disruptor. 
Moms Across America found high levels of glyphosate in breast 
milk samples from lactating mothers.4 The increased use of 
glyphosate has been linked with numerous modern diseases 
(126, 128). There is a correlation coefficient of R = 0.99 when 
comparing the number of children with autism and the amount 
of glyphosate applied to corn and soy crops between the years 
1991 and 2010 (126). It remains to be determined if bioactive 
components in soy have been altered by genetic modification. 
3 FDA market basket study, http://www.fda.gov/Food/FoodScienceResearch/
TotalDietStudy/ucm184232.htm.
4 Moms Across America, http://www.momsacrossamerica.com/tags/glyphosate.
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The United States Department of Agriculture supports the 
Database for the Isoflavone Content of Selected Foods. The latest 
version, Release 2.0, was released in September 2008 and pro-
vides daidzein, genistein, glycitein, and total isoflavone levels for 
soy protein isolate and SIF,5 which is summarized in Table 6. It is 
not possible to discern from these data if isoflavone levels have 
changed in response to genetic modification as Release 2.0 from 
2008 is based on data from 1997, which is prior to widespread 
use of GM soy.
Glyphosate is absorbed by soybean plants with higher concen-
trations found in plants that are sprayed several times and when 
treatments occur during the flowering stage (129). Glyphosate 
can affect the nutritional content of soy as well as human immu-
noreactivity. Organic soybeans (glyphosate-free) exhibit higher 
sugar, total protein, and zinc levels and less fiber, total fat, and 
omega-6 fatty acids than GM soy (glyphosate-contaminated) 
(130). When sera from patients with a soy allergy was used to 
screen immunoblots of GM and wild soybeans, a unique 25 kDa 
protein band was observed with the GM soy (131). The USDA 
Pesticide Data Program is a national pesticide residue monitoring 
program that produces the most comprehensive pesticide residue 
database in the United States.6 The mission of the program is to 
help monitor the safety of America’s food supply. Between the 
years 1991 and 2015, glyphosate residue levels were only meas-
ured in one year (2011). Considering that glyphosate is the most 
commonly used pesticide in the United States, it is unfathomable 
and irresponsible that the USDA does not include this chemical 
in their yearly screening. In 2011, 300 soybean samples were 
tested and 271 (90.3%) contained glyphosate at levels ranging 
from 0.26 to 18.5 ppm.
soy is associated with negative Health 
outcomes
Diet has strong potential to affect health including neurological, 
immune, and endocrine function. Industrial soy foods have 
been implicated as a possible cause of Alzheimer’s disease with a 
log–log correlation of soy consumption and Alzheimer’s disease 
mortality of r = 0.24, p < 0.05 (132). It was long thought that 
large macromolecules do not pass directly from the digestive 
tract to the circulatory system. Emerging evidence is proving 
this paradigm false. Meal-derived DNA fragments that are 
large enough to carry intact genes can avoid degradation by 
the stomach acid, enter the human circulatory system, and are 
detected in blood plasma (133, 134). In addition to plant DNA, 
greater than 90% of soybeans are GM and carry bacterial genes 
that can code for toxic proteins. It has been estimated that if 
there was a one in a billion event of bacterial transformation 
of GM DNA into gut bacterium, that with 1E15 bacteria in the 
human gut, one would potentially have one million transformed 
bacteria in the intestines (127). These transformed bacteria 
could constitutively express toxic proteins that could damage 
5 Bhagwat S (2008) USDA database for the isoflavone content of selected foods, 
release 2.0. Nutrient data laboratory home page, http://www.ars.usda.gov/
nutrientdata/isoflav.
6 USDA Pesticide Data Program, https://www.ams.usda.gov/datasets/pdp.
the intestinal lining and cause disorders like celiac disease in 
which peptides enter the circulatory system, stimulate antibody 
production, and lead to autoimmune reactions that affect neu-
rological function. The second most common GM trait codes 
for a built-in pesticide produced by the soil bacterium Bacillus 
thuringiensis.
There have been studies examining cognitive and repro-
ductive development in infants fed SIF. Malloy and Berendes 
(135) tested 9- to 10-year-old children fed SIF or human milk 
during their first year of life and found no difference in intel-
ligence quotient, behavioral problems, learning impairment, or 
emotional problems. A study by Strom and colleagues (136) 
surveyed adults aged 20–34  years old who had participated 
as infants in controlled feeding studies between 1965 and 
1978 (Generation X). The study population included 811 
subjects, which was 85% of the original cohort, including 
males (n = 120) and females (n = 128) who had been fed SIF. 
The outcomes were no correlation was found between infant 
formula use and education level, but women in the soy cohort 
reported longer duration of menstrual bleeding (about 8  h) 
and greater discomfort with menstruation. The soy cohorts 
also had a higher reported use of asthma or allergy drugs and 
greater tendency toward sedentary activities. Consumption of 
SIF has also been associated with breast development (137) 
and premature thelarche (133).
We found that soy-based diets are associated with increased 
propensity for seizures in both mouse and human models of 
neurological disease (138, 139). A literature search of the terms 
“soy” AND “seizure” produces very few studies. In humans, 
there are several case reports involving infants with seizure 
phenotypes in response to consumption of defective SIF or 
who developed micronutrient deficiencies due to SIF (reviewed 
in Data Sheet S2 in Supplementary Material). There have been 
several rodent studies assessing the effect of soy phytoestrogens 
on seizures. The problem with studying soy in rodents is that 
they metabolize phytoestrogens differently than humans. Thus, 
the data may not be generalizable between species. It should 
be noted that infants can efficiently digest, absorb, and excrete 
genistein and daidzein from SIF (140). Rodents conjugate 
isoflavones less efficiently and thus have higher circulating 
concentrations of biologically active forms (9). With this caveat 
noted, studies in rats and mice have demonstrated that soy 
increases seizures.
soy diet is associated with seizures 
in rodents
Mohammadpour and colleagues (141) studied the effects of 
soy extract on pentylenetetrazole (PTZ)-induced seizures in 
the presence/absence of ovarian hormones in rats as well as 
gender-dependent differences in the effects of phytoestrogens 
on behavior. The study population included 72 Wistar rats, 
male and female, aged 2 months. The independent variable was 
soy extract, and the dependent variable was seizure latency. 
The cohorts included male/saline, male/low-dose soy, male/
high-dose soy, sham/saline, sham/low-dose soy, sham/high-
dose soy, ovariectomized/saline, ovariectomized/low-dose soy, 
taBLe 7 | increased incidence of comorbid disorders associated with the 
use of soy-based infant formula.
soy non-soy
N % N % Pa,c Cib
Females
Allergies 44 6.8 217 1.8 0.1 0.7–22
ADHD 44 6.8 217 2.8 0.2 0.5–12
Asthma 44 4.5 217 9.2 0.5 0.1–2.2
Bipolar 42 14.3 217 15.7 1.0 0.3–2.5
Males
Allergies 297 3.0 1,391 1.4 0.06 0.9–5.0
ADHD 297 6.7 1,391 4.0 0.04 1.0–3.0
Asthma 297 8.4 1,391 4.9 0.02 1.1–2.9
Bipolar 273 23.8 1,390 15.2 0 1.3–2.4
Genders combined
Allergies 341 3.5 1,608 1.5 0.01 1.1–5.2
ADHD 341 6.7 1,608 3.9 0.04 1.0–3.0
Asthma 341 7.9 1,608 5.5 0.08 0.9–2.4
Bipolar 315 22.5 1,607 15.2 0.001 1.2–2.2
aFisher’s exact test.
b95% confidence intervals.
cChi-squared analysis.
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and ovariectomized/high-dose soy. Low-dose soy groups were 
treated with 20 mg/kg soy extract for 2 weeks. High-dose soy 
groups were treated with 60 mg/kg soy extract for 2 weeks. Sham 
controls were injected with saline instead of soy extract. Seizures 
were induced with 90 mg/kg body weight PTZ (intraperitoneal 
injection). The latency to minimal clonic seizures and general-
ized tonic–clonic seizures were recorded. The outcome was that 
latency to minimal clonic seizure was shorter in male rats treated 
with either dose of soy extract and was dose dependent. Latency 
to generalized tonic–clonic seizure was shorter in male rats 
treated with either dose of soy extract, but not dose dependent. 
There was no effect with either dose of soy extract in female rats 
with either seizure type. The ovariectomized females responded 
similarly as males.
Work from our laboratory (138) compared seizure rates in 
several transgenic and knockout mouse models of neurological 
disease in response to a soy/grain-based versus a casein-based 
diet. We found significantly elevated seizure rates when the mice 
were fed soy-based diet. The study population was 452 C57BL/6 
mice, male and female, aged postnatal day 21. The independent 
variables were diet (casein versus soy based) and genotype. The 
dependent variable was seizure propensity. The methodology 
included assessment of audiogenic seizure susceptibility by 
exposing mice to a 110 dB alarm for 5 min and measuring latency 
time to wild running, seizure, and death. The cohorts included 
wild-type, Tg2576, Ts65Dn, FRAXAD, and Fmr1KO mice. The 
outcome was that transgenic mouse lines that model fragile X 
syndrome, Alzheimer’s disease, and Down syndrome exhibit 
increased seizures when maintained on a soy-based compared 
to a casein-based diet. Supplementation of the casein diet with 
soy protein isolate or individual isoflavones did not statistically 
increase seizures in the Tg2576, although daidzein elicits a sta-
tistically significant increase in wild running in wild-type mice. 
Thus, a combination of dietary factors and/or agrochemicals may 
contribute to seizure susceptibility.
The Ebrahimzadeh Bideskan study (142) investigated the 
effects of soy extract on PTZ-induced seizures in ovariecto-
mized rats. The study population included 60 Wistar female 
rats that were 2  months old. The rats were divided into four 
groups: sham, low-dose soy, high-dose soy, and ovariectomized. 
Each group was divided into two subgroups that received either 
a low dose of PTZ (40  mg/kg body weight, intraperitoneal) 
for 14  days or a single injection of PTZ (90  mg/kg body 
weight, intraperitoneal). The soy cohorts were injected with 
20 and 60  mg/kg body weight of soy extract 30  min before 
each PTZ injection. The sham mice received saline instead 
of soy extract. The independent variable was soy extract, and 
the dependent variable was seizure propensity. The outcome 
was seizure scores, which were lower for the ovariectomized 
group than the sham group. Both of the soy groups had higher 
scores compared with the ovariectomized group. A single 
injection of high-dose PTZ significantly increased general-
ized tonic–clonic seizure but not minimal clonic seizure in 
the ovariectomized rats compared with sham. Treatment with 
either soy dose significantly decreased latency to generalized 
tonic–clonic seizure and minimal clonic seizure compared with 
ovariectomized group.
In addition to the aforementioned rodent studies, the effects 
of soy have been studied in monkeys and in vitro. Dietary soy 
is associated with epigenetic changes in monkeys such that 
overall methylation in liver and muscle tissue was increased 
when switching from a soy-based to casein-based diet (143). 
At  high doses, genistein and daidzein are toxic to primary 
neuronal cultures (144).
soy diet is associated with seizures and 
other Health disorders in Humans
We conducted a retrospective analysis of the Simons Foundation 
Autism Research Initiative (SFARI) medical record database 
(139). There was a 2.6-fold higher rate of febrile seizures, a 2.1-
fold higher rate of epilepsy comorbidity, and a 4-fold higher rate 
of simple partial seizures in autistic children fed SIF. In addition to 
seizures, there was an increased incidence of allergies, attention-
deficit hyperactivity disorder, asthma, and bipolar disorder in the 
SIF cohort (Table  7). Limitations of the study included infant 
formula and disease data were based on parental recall, and there 
was a lack of data regarding potentially confounding issues such 
as why the subjects used SIF and for how long.
Maternal health, ethnicity, and geography likely play roles in 
the choice to feed SIF. Autoimmune disease in mothers with the 
fragile X mental retardation gene premutation is associated with 
seizures in their children with fragile X syndrome (145). In the 
SFARI autism population, seizure incidence was not more preva-
lent in the proband if the mother had an autoimmune disorder 
(Table S1 in Supplementary Material). However, autistic children 
reported to have been fed SIF were 3.5-fold (females) and 2.3-
fold (males) more likely to have mothers with an autoimmune 
disorder (Table S2 in Supplementary Material). Thus, when the 
mother had an autoimmune disorder, her autistic child was twice 
as likely to have been fed SIF (31 versus 16%). The lack of an 
association between proband seizure incidence and maternal 
FiGUre 2 | infant formula and disease. As many as 25% of infants 
consume soy-based infant formula during their first year of life, but there is a 
paucity of information regarding potential adverse health effects (139, 152–158).
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autoimmune status suggests that maternal autoimmunity is not 
a confounding factor for seizure prevalence in response to SIF. 
Although the number of subjects was small, there was a trend 
for increased use of SIF among African-Americans (Table S3 in 
Supplementary Material). There was a twofold increase in the 
percentage of children fed SIF in central North America (24%) 
versus both eastern (14%) and western (12%) North America 
(P = 0 for both comparisons). The percentage of autistic subjects 
from the SFARI database from central North America was 36.8%; 
yet, this population accounted for 51.2% of the subjects fed SIF 
suggesting that SIFs are disproportionately used in the central 
United States. Regarding SES factors in the SFARI population, the 
education of the mothers was not statistically different dependent 
on SIF use in their autistic children (66% of mothers of females 
fed non-soy-based formula graduated from college or higher, 
61% for males fed non-soy-based formula, 56% for females fed 
SIF, and 58% for males fed SIF).
In addition to neurological and immune health, soy 
isoflavones affect development of the intestines as well as the 
makeup of the intestinal microbiota (146). There have been two 
studies investigating the influence of SIF on the gut microflora 
in infants and/or children. The first study found increased 
equol excretion in the soy group (19%) compared to controls 
(5%) with elevated Bifidobacteria, Bacteroides, and Clostridia 
bacteria in fecal samples from the soy group (147). The second 
study found elevated Bifidobacteria species (B. adolescentis and 
B. infantis), which were not detected before commencing the SIF 
(148). Bifidobaterium, Bacteriodes, and Clostridium are among 
the human intestinal bacteria that can produce S-equol (149, 
150). S-equol is the biologically active metabolite of daidzein. 
Intestinal bacteria transform daidzein to equol in humans that 
are equol producers. In Japan, Korea, and China, up to 80% of 
people are equol producers, but as few as 25% of people in North 
America and Europe can biotransform daidzein into equol 
(150). Equol modulates expression of the BRCA1 and BRCA2 
breast cancer genes through an epigenetic mechanism resulting 
in decreased methylation, which results in an increased level 
of oncosuppressors in breast cancer cell lines (151). The effect 
of equol on the methylation of neuronal genes has not been 
studied.
In summary, much remains to be learned regarding the effects 
of soy, soy constituents, and contaminating agrochemicals on 
health. There are conflicting reports in the literature regarding 
the health benefits associated with soy consumption in adults. 
There is a dearth of studies examining potentially toxic compo-
nents and contaminants of soy. There is emerging data regarding 
adverse health effects associated with soy consumption. SIF RCT 
to date have involved healthy infants or infants with allergies, 
persistent diarrhea, or atopic dermatitis. There are no published 
trials assessing the effects of SIF on children with developmental 
disabilities. These vulnerable groups may be more susceptible 
to seizure promoting ingredients and/or chemicals in the diet. 
Overall, lack of knowledge related to the effects of SIF and 
agrochemicals on health could be equated with the state of affairs 
of cigarette smoking in the 1950s when smoking was generally 
regarded as safe. Over 50  years after the Surgeon General first 
warned of the health hazards of smoking, tobacco use is still a 
large burden in the United States where 18% of adults smoke.7 
Decades later, there are no RCT that prove smoking causes lung 
cancer; however, enough evidence has accumulated where an 
RCT would be unethical. One could envision a similar scenario 
unfolding as evidence accumulates regarding adverse health 
effects associated with agrochemicals and GM food. A summary 
of the known effects of infant feeding on childhood development 
is provided in Figure 2.
transGeniC eGF siF to treat 
neCrotiZinG enteroCoLitis
PLoS One recently published an article by He and colleagues 
entitled, “Transgenic Soybean Production of Bioactive Human 
Epidermal Growth Factor (EGF),” in which the authors propose 
that soybean seeds could be utilized as a biofactory for the pro-
duction of therapeutic agents such as epidermal growth factor 
(EGF), which could then be delivered to infants in a soymilk 
platform for the treatment of diseases such as necrotizing 
enterocolitis (NEC) (159). NEC, the second most common cause 
of death in premature infants, is a serious condition that occurs 
when the intestinal tissue is damaged and begins to die (160). The 
mission to prevent or treat devastating disorders including NEC 
is laudable. However, the strategy in this article raises several 
serious concerns.
First, the American Academy of Pediatrics concluded that SIFs 
are not recommended for preterm infants due to increased risk 
of osteopenia (161). SIFs are also not indicated in the manage-
ment of documented cow milk protein-induced enteropathy or 
enterocolitis because of the high frequency of sensitivity to both 
cow milk and soy antigens in infants (161). Breast milk feedings 
are associated with a decrease in NEC in premature infants. Thus, 
7 The Health Consequences of Smoking – 50  years of Progress. A report of the 
Surgeon General, http://www.surgeongeneral.gov/library/reports/50-years-of-
progress/exec-summary.pdf.
taBLe 8 | secondary analysis of He et al. non-targeted metabolome set 
(159).
Fold change (epidermal growth factor/Wt)
Charged amino acids
Arginine 0.71
Lysine 1.49*
Aspartic acid 1.25
Glutamic acid 1.19
polar amino acids
Glutamine 1.14
Asparagine 0.48
Histidine 1.41*
Serine 1.04
Threonine 1.19*
Tyrosine 0.82
Cysteine 1.2
Methionine 1.22*
Tryptophan 1.34*
Hydrophobic amino acids
Alanine 1.26*
Isoleucine 1.55*
Leucine 1.09
Phenylalanine 1.08
Valine 1.38*
Proline 1.29*
Glycine 1.29*
P < 0.05 by Welch’s two-sample t-Test.
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a soymilk platform for drug delivery would not be recommended 
to prevent NEC.
Second, there are strong data that EGF is protective against 
the development of NEC; however, that evidence comes in the 
context of breast milk (162). Breast milk inhibits lipopolysaccha-
ride receptor, toll-like receptor 4, within intestinal epithelium, but 
not in mice lacking epidermal growth factor receptor (EGFR). 
Overexpression of toll-like receptor 4 in the intestinal epithelium 
reversed the protective effects of breast milk. Selective removal 
of EGF from breast milk reduced the protective properties. To 
our knowledge, there ares no data examining the effects of EGF 
supplementation in a SIF platform on NEC or any other disor-
der. There is a wealth of literature with respect to the effects of 
isoflavones on EGFR signaling. Importantly, the most prevalent 
isoflavone in soy is genistein, which can reduce EGF-mediated 
DNA synthesis (163), decrease EGFR levels (164, 165), decrease 
or increase phosphorylation of EGFR (166, 167), and transacti-
vate EGFR (168).
Third, there are several questionable data interpretation 
issues with this article. In their Figure 3, the authors claim that 
the human EGF produced in soybeans is the same molecular 
weight as commercially available recombinant human EGF; 
however, the recombinant EGF appears at least 0.5 kDa larger 
by immunoblot analysis (159). In their Figure 4, mass spec-
trometry analysis indicated that exact matches for peptides 
encompassing the majority (not all) of the complete mature 
soy EGF were obtained (159). The authors recognize that plant 
tissues possess biologically active components that could mask 
or enhance the effects of the soy EGF. In their Figure 5, they 
claim that SIF is biologically inactive because it does not modify 
the internalization, degradation, or phosphorylation of EGFR 
in HeLa cells (159). This finding is surprising considering the 
published literature regarding the effects of genistein on EGFR 
and suggests that HeLa cells are not the appropriate cell type 
to discern SIF-induced biological activities. In their Figure 
6, the authors claim that there are insignificant differences in 
the small molecule profile between non-transgenic soybeans 
and those producing EGF except for the metabolites involving 
sulfur amino acid metabolism. There is a 19.4-fold increase in 
S-methylmethionine, an 8.24-fold increase in glucorante, and a 
1.65-fold increase in skikimate (159). However, a closer analysis 
of their non-targeted metabolome set indicates that there are sta-
tistically significant increases in 10 of 20 amino acids (Table 8). 
Infants who have NEC have selective amino acid deficiencies, 
such as glutamine and arginine, that may predispose to the ill-
ness (169). All of the statistically significant differences between 
the EGF and non-transgenic soybeans were toward an increased 
level in the transgenic samples indicating that deficiencies in 
these amino acids should not be an issue; however, the effect of 
altered ratios of the amino acids is not known.
Additional concerns include the strong promoter and termi-
nator used to regulate gene expression of EGF in soybeans as well 
as the hygromycin resistance gene in the construct. Meal-derived 
DNA fragments that are large enough to carry complete genes 
can avoid degradation in the digestive system and pass into 
human blood (134). Theoretically, the soy EGF construct could 
be transformed into gut bacteria where it could constitutively 
produce EGF (127). The odds of bacterial transformation in 
preterm infants may be greater due to an underdeveloped 
microbiota.
testaBLe HypotHeses to sUpport/
neGate tHe deVeLopMent oF 
tHerapeUtiC siF
Testable hypotheses to support the development of therapeutic 
SIF (written in the alternative): (1) SIF causes altered reproductive, 
immune system, and/or cognitive development. This hypothesis 
can be addressed through longitudinal and retrospective RCT. 
For example, The Beginnings cohort can be tested at adolescent 
and adult ages. The Andres study (2) did not find alterations in 
reproductive organs at 5 years of age in response to SIF; however, 
puberty may be a more appropriate age to discern effects. Soy-
based diets can affect reproductive tissue growth and hormone 
secretion in male rats (170). In addition to reproductive organs, 
allergy and cognitive testing at multiple stages of development 
could discern differences in immune system and cognitive 
development. The retrospective study by Strom and colleagues 
(136) found associations with menstrual, asthma, and allergy 
phenotypes in relation to infant diet. Our retrospective analysis 
of the SFARI medical record database found a 3.5-point decrease 
in intelligence quotient in autistic girls fed SIF (not statistically 
significant in a cohort of 253 subjects). Rhesus monkeys fed 
SIF do not show effects on growth, health, developmental mile-
stones, temperament ratings, or stereotypy but do exhibit altered 
diurnal rhythms and reduced play behavior (171). Secondary 
analyses of national survey data such as the National Health and 
Nutrition Examination Survey data, a nationally representative 
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population of 1,864 infants in which 12% of babies consumed 
SIF, could identify associations between infant diet and comor-
bid disorders (172).
(2) Glyphosate is associated with adverse health effects. This 
hypothesis can be addressed through longitudinal RCT with 
subjects randomly assigned to organic versus conventional 
diets. Comorbid disorders of particular interest for the study are 
autism, diabetes, thyroid cancer, and Alzheimer’s and Parkinson’s 
disease where incidence or death rates have grown rapidly since 
the introduction of GM food and use of glyphosate (126). In 
addition to RCT, the potential long-term effects of glyphosate 
could be studied in animal models, particularly in regard to body 
composition, obesity, and micronutrient deficiencies/toxicity. For 
example, glyphosate disrupts cytochrome P450 enzymes and is 
associated with manganese deficiency and toxicity (126). SIFs are 
naturally high in manganese (up to 200× higher than breast milk), 
and while an essential nutrient, it can also act as neurotoxin (173, 
174). The combination of SIF and glyphosate and their combined 
effects on manganese levels may exacerbate adverse health effects 
similar to the exponential increase in lung cancer with combined 
exposure to cigarette smoking and asbestos.
(3) SIF and glyphosate adversely affect the human gut micro-
biota, and (4) GM DNA is transferred to human gut bacteria. These 
hypotheses could be tested by screening the bacterial content of 
human fecal samples as a function of diet. There is evidence from 
women in Canada who ate a typical diet including GM soy, corn, 
and potatoes of the presence of the bacterial toxin B. thuringiensis 
in maternal and fetal blood (175). Thus, the toxin can cross the 
placenta. It remains to be determined if the pesticides in the blood 
came directly from the food and/or if GM DNA was incorporated 
into gut bacteria to form pesticide-producing factories in the 
intestines.
And (5) adverse health effects associated with SIF and glypho-
sate are more detrimental in individuals genetically predisposed 
to developmental disabilities. This hypothesis could be tested in 
transgenic animal models or by retrospective analysis of medical 
records. Porcine or primate models would be more advantageous 
than rodents, which conjugate isoflavones less efficiently.
pUBLiC poLiCy disCUssion
In 1826, Anthelme Brillat-Savarin said, “Tell me what you eat and 
I will tell you what you are.” The field of food science is rapidly 
evolving. As a society, we have moved in fast forward away from 
knowing what we are eating or where and how it is produced. 
Food replicators featured in the futuristic television shows The 
Jetsons and Star Trek are here in the form of 3D food printers. 
Refrigerators can identify spoiled food and order groceries. But 
unlike Star Trek, technology has not advanced to where we have 
medical tricorders to instantly diagnose the effects of environ-
mental exposures including diet and agrochemicals on human 
health. Considering the importance of diet to child development, 
a public discussion on the merits of therapeutic SIF is in order. 
Issues that need to be addressed include the following: (1) rigor-
ous and longitudinal study of the biological effects of endogenous 
and contaminating components of SIF and therapeutic SIF on 
health, (2) identification of disease populations that may benefit 
or be harmed from therapeutic SIF, and (3) the ethics of national 
supplementation of food products.
rigorous and Longitudinal study
Rigorous and longitudinal study of the biological effects of soy, 
both conventional and GM, on development and disease propen-
sity is required. The current literature consists of numerous con-
flicting reports and potentially confounding variables regarding 
soy consumption. Therapeutic SIF would presumably be consid-
ered a medical food product, which are consumed under medical 
supervision but do not require a prescription. We need to discuss 
as a society what level of evidence is required to prove safety and 
efficacy of these types of products, and then, we need to conduct 
studies at that level prior to public consumption. A large percent-
age of the population will not be satisfied with FDA oversight 
alone. At the national level, we are in the midst of a heated debate 
regarding GM foods, which have been approved by the FDA. The 
Mellman Group found that 88% of Americans are in favor of 
requiring labels for foods that contain GM ingredients. Sixty-four 
other countries have the right to know whether their food is GM. 
Yet in 2016, the United States Senate and House of Representatives 
voted in favor of the Safe and Accurate Food Labeling Act (a.k.a. 
the DARK Act, Deny Americans the Right-to-Know Act), which 
blocks states from issuing mandatory food labeling laws for GM 
foods. The effects of GM soy consumption have not been studied 
in humans and are not monitored. Widespread farming of GM 
crops has exponentially increased glyphosate usage (126), the 
effects of which have also not been studied nor monitored. An 
unanticipated problem of glyphosate usage on GM crops was that 
weeds growing among the crops became resistant to the herbicide 
(176), which has spurred increased application of the chemical 
over time for weed control.
identification of Vulnerable disease 
populations
We need to identify populations that may benefit or be harmed 
from therapeutic SIF. Our understanding at this time of how 
diet interacts with genes, gender, and ethnicity is very limited. 
Of interest, in the Andres study (2), the parents were allowed 
to choose the diets they were going to feed their infant before 
enrollment in the study. African-Americans constituted 8.9% 
of the total study population (9 of 101 subjects); yet, parents of 
eight of those subjects chose to feed their infants SIF resulting in 
a significant increase in African-American representation in the 
SIF cohort (23.5%) compared to 0% in the breast-fed and 3.1% 
in the cow milk-based cohort. Our analysis of the SFARI medical 
records also indicated that an increased percentage of African-
American infants were fed SIF (139). This raises important 
concerns regarding SES factors that may affect formula choice 
and disease outcomes. Because of perceived lactose intolerance, 
African-American babies may be more likely to receive SIF. NEC 
is three-fold higher in African-Americans than Caucasians (160), 
and SIF is not recommended for treatment. African-American 
girls enter puberty and reach menarche earlier than Caucasian 
and Hispanic girls (177). SIF is associated with very early as well 
as late menarche (178, 179), and with heavy menstrual bleeding 
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and larger uterine fibroids among African-American women 
(180, 181). The Andres study (2) tested reproductive organ size 
at 5 years of age with a planned follow-up study at puberty. The 
data collected in the follow-up study can be compared with any 
reported menstrual problems. Analysis of the National Health 
and Nutrition Examination Survey data indicated that higher 
consumption of SIF was associated with increased family income 
and level of education (172). SIF is widely used in Israel, where 
it constitutes 31.5% of infant formula sales (70% of children 
receive soy for greater than 6 months) (182). There is a high rate 
of ADHD (12.6%) in Israel (183). Thus, there may be ethnic and 
SES populations that are more likely to consume SIF and thus 
more susceptible to adverse health effects.
the ethics of national supplementation 
of Food
Finally, the ethics of supplementation of food products needs to 
be discussed. Concerns include containment of GM crops and 
national fortification of foods for population-wide consumption. 
If therapeutic soybeans are grown in the open, cross pollination 
between neighboring farms could contaminant non-transgenic 
crops. If a micronutrient or protein of interest is deemed beneficial 
to health, it could be mass produced in soybeans. Soy protein is 
already extensively used as an additive by the food industry in the 
United States in nearly all types of foods. Two current examples 
of national supplementation of our food and water are folic acid 
and fluoride, and both are associated with adverse health effects 
in some people.
In 1998, the FDA began requiring food manufacturers to 
enrich grain products with folic acid with the goal of prevent-
ing neural tube birth defects. Folate is found naturally in leafy 
green vegetables and citrus fruits, but not all pregnant women 
were consuming enough resulting in birth defects such as spina 
bifida due to folate deficiency. Folic acid is an inactive, more stable 
form of folate that is added to food. Normally, the body converts 
folic acid to folate; however, persons with mutations in the 
methylenetetrahydrofolate reductase gene cannot process folic 
acid and it builds up in the body. In the United States, up to 60% 
of the population is heterozygous and up to 25% homozygous 
for methylenetetrahydrofolate reductase genetic mutations (184). 
Most individuals are unaware that they have these gene defects, 
and consumption of excess folic acid may increase the risk for 
miscarriages, autism in offspring8 (185), and some types of cancer 
(186, 187). In addition, folic acid can interact with medications 
such as antiepileptic drugs. Thus, while supplementation of the 
national food supply with folic acid has decreased neural tube 
defects by 25–30% (188), it may be causing health problems for 
other portions of the population. Similarly, fluoride supplementa-
tion has a modest benefit in reducing dental caries, but is associ-
ated with decreased intellectual ability, hypothyroidism, dental 
and skeletal fluorosis, enzyme and electrolyte derangement, and 
uterine cancer (189). There is a significant problem in obtaining 
8 Johns Hopkins University Bloomberg School of Public Health. Too much folate in 
pregnant women increases risk for autism, study suggests: Researchers say that while 
folate deficiency is bad for developing fetus, excessive amounts could also be harm-
ful. ScienceDaily, www.sciencedaily.com/releases/2016/05/160511105352.htm.
the optimal dose of bioactive agents when using food or water 
supplementation because exposure is not controlled.
Overall in 2016, we are far from understanding the effects 
(good or bad) of food on health and disease and could be 
exacerbating disorders like autism, Alzheimer’s disease, and 
cancer by increased exposure to chemicals through modern 
food growth and manufacturing processes. A critical review 
of the marketing claims on infant formula products in the 
United States indicates that there is insufficient evidence to 
support claims regarding reducing lactose, using hydrolyzed 
or soy protein, or adding pre-/probiotics to formula to aid in 
reducing fussiness, gas, or colic (190). Therapeutic SIF may be 
technologically feasible and economical; however, are they safe 
and biologically relevant?
Both sides in this debate could argue that there is a lack of 
funding to conduct the rigorous studies required to prove their 
positions. A search of the National Institutes of Health Reporter 
website with the term “soy infant formula” indicates only five 
funded grants. Those applications are studying the effect of 
SIF on the prevention of uterine fibroids, establishment of the 
gut microbiota, and the growth and development of estrogen-
responsive tissue. In addition, there are studies on the effect of 
neonatal genistein exposure on glucocorticoid receptor signal-
ing and function in the uterus and how genistein affects female 
reproductive tract development and function. A search with 
the term “genetically modified soy” returns a study on the aller-
genicity of genetically modified food proteins, a study testing 
the effect of Roundup on neuronal degeneration in nematodes 
(worms), and a funded core facility to maintain a greenhouse for 
pharmaceutical producing plants. The remaining search results 
involved genetically modified animals and were not studying 
the effects of a genetically modified food product. A search with 
the term “glyphosate” returned two studies examining occupa-
tional exposure to pesticides and the risk of cancer. Thus, much 
remains unstudied regarding the health effects of SIF, associated 
agrochemicals, and therapeutic SIF.
In summary, SIF constitute approximately 12% of the infant 
formula market (82). Approximately a quarter of babies are fed 
SIF  for some time during their first year of life, although data 
are lacking regarding how many are exclusively fed SIF (117). 
Proponents of therapeutic SIF argue that the long time and 
widespread use of SIF in conjunction with normal growth metrics 
suggest that these formulas are a safe, healthy, and inexpensive 
alternative to cow milk-based infant formula. Opponents believe 
more rigorous study is required. The question is do we chance error 
on the side of technology, economics, and innovation and move 
forward with the development of therapeutic SIF or do we take a 
more prudent approach and put proven safety and efficacy first.
etHiCs stateMent
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